Apar Pataer Selected Research

Apar Pataer Research Topics

22	Neoplasms (Cancer) 04/2024 - 01/2011
16	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2023 - 05/2012
16	Lung Neoplasms (Lung Cancer) 11/2022 - 01/2012
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022
1	Epstein-Barr Virus Infections 01/2022
1	Lymphoma (Lymphomas) 01/2022
1	Pathologic Complete Response 01/2021
1	Disease Progression 01/2021
1	Granuloma 01/2021
1	Aneuploidy (Aneuploid) 01/2019
1	Breast Neoplasms (Breast Cancer) 01/2019
1	Carcinogenesis 10/2018
1	Sepsis (Septicemia) 02/2018
1	Agranulocytosis (Granulocytopenia) 02/2018
1	Exanthema (Rash) 02/2018
1	Hypokalemia 02/2018
1	Infections 02/2018
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 02/2018
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2018
1	Adenocarcinoma 01/2018
1	Hypersensitivity (Allergy) 01/2017

7	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2013
6	Proteins (Proteins, Gene)FDA Link 04/2024 - 01/2011
4	NivolumabIBA 10/2023 - 01/2021
4	IpilimumabIBA 10/2023 - 01/2021
4	eIF-2 Kinase (eIF 2 Kinase)IBA 01/2020 - 03/2013
2	Immune Checkpoint InhibitorsIBA 11/2022 - 01/2021
2	Small Interfering RNA (siRNA)IBA 01/2019 - 10/2018
2	Phosphotransferases (Kinase)IBA 10/2018 - 09/2015
2	Formaldehyde (Formol)FDA Link 01/2018 - 01/2018
2	ParaffinIBA 01/2018 - 01/2018
2	EnzymesIBA 09/2015 - 01/2013
1	RG7388IBA 01/2022
1	Prion ProteinsIBA 01/2020
1	navitoclaxIBA 01/2020
1	trametinibIBA 01/2020
1	Silicon Dioxide (Silica)FDA LinkGeneric 01/2019
1	Thioredoxin-Disulfide ReductaseIBA 01/2019
1	cobalt ferriteIBA 01/2019
1	Glutathione Reductase (Glutathione-Disulfide Reductase)IBA 01/2019
1	Glutathione (Reduced Glutathione)IBA 01/2019
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 10/2018
1	Elongation Factor 2 KinaseIBA 10/2018
1	matrigelIBA 10/2018
1	Mitogen-Activated Protein KinasesIBA 10/2018
1	Cyclin D1IBA 10/2018
1	Cisplatin (Platino)FDA LinkGeneric 02/2018
1	Docetaxel (Taxotere)FDA Link 02/2018
1	PlatinumIBA 02/2018
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 02/2018
1	LigandsIBA 01/2018
1	taxaneIBA 01/2017
1	Histones (Histone)IBA 01/2017
1	AMP-Activated Protein KinasesIBA 05/2015
1	AntibodiesIBA 03/2013
1	ImmunosorbentsIBA 01/2013
1	Insulin-Like PeptidesIBA 01/2013
1	Cyclin B1IBA 01/2012
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2011
1	Messenger RNA (mRNA)IBA 01/2011

13	Neoadjuvant Therapy 10/2023 - 05/2012
9	Therapeutics 01/2022 - 01/2018
5	Drug Therapy (Chemotherapy) 10/2023 - 01/2017
3	Immunotherapy 01/2021 - 01/2019
2	Radiotherapy 01/2019 - 06/2016
1	Cardiopulmonary Resuscitation (CPR) 11/2022
1	Aftercare (After-Treatment) 01/2020
1	Perioperative Period 02/2018